Saturday, June 20, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,771
Drugs linked 4,798

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 840 of 1,261

  1. US 8597898

    Fusion polypeptides capable of activating receptors

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 3, 2013 · Expires Nov 28, 2033

    granted

  2. US 8597883

    Biomarkers for cancer-related fatigue and use thereof

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Dec 3, 2013 · Expires Nov 28, 2033

    granted

  3. US 8598139

    Lipid formulated dsRNA targeting the PCSK9 gene

    Alnylam Pharmaceuticals, Inc. · Granted Dec 3, 2013 · Expires Nov 28, 2033

    granted

  4. US 8598164

    Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels

    Vertex Pharmaceuticals Incorporated · Granted Dec 3, 2013 · Expires Nov 28, 2033

    granted

  5. US 8598154

    Pyridyl-amine fused azadecalin modulators

    Corcept Therapeutics Incorporated · Granted Dec 3, 2013 · Expires Nov 28, 2033

    granted

  6. US 8597946

    Enhanced dendritic cells for cancer immunotherapy

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Dec 3, 2013 · Expires Nov 28, 2033

    granted

  7. US 8597655

    Recombinant fusion protein and polynucleotide construct for immunotoxin production

    The Medical Research, Infrastructure and Health Services Fund of the Tel-Aviv Medical Center · Granted Dec 3, 2013 · Expires Nov 28, 2033

    granted

  8. US 8597616

    Dry powder drug delivery formulations, methods of use, and devices therefore

    The Board of Regents of the University of Texas System · Granted Dec 3, 2013 · Expires Nov 28, 2033

    granted

  9. US 8598364

    Oligomer-protease inhibitor conjugates

    Nektar Therapeutics · Granted Dec 3, 2013 · Expires Nov 28, 2033

    granted

  10. US 8598322

    Anti CEACAM1 antibodies and methods of using same

    TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD. · Granted Dec 3, 2013 · Expires Nov 28, 2033

    granted

  11. US 8598321

    Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins

    The Regents of the University of California · Granted Dec 3, 2013 · Expires Nov 28, 2033

    granted

  12. US 8598333

    SiRNA silencing of genes expressed in cancer

    Alnylam Pharmaceuticals, Inc. · Granted Dec 3, 2013 · Expires Nov 28, 2033

    granted

  13. US 8598312

    Inhibitors of antigen presentation by MHC class II molecules

    Provid Pharmaceuticals Inc. · Granted Dec 3, 2013 · Expires Nov 28, 2033

    granted

  14. US 8598313

    Compositions for ameliorating cell proliferative disorders and methods of making and using them

    The Regents of the University of California · Granted Dec 3, 2013 · Expires Nov 28, 2033

    granted

  15. US 8598226

    Fused cyclic compounds

    Takeda Pharmaceutical Company Limited · Granted Dec 3, 2013 · Expires Nov 28, 2033

    granted

  16. US 8598205

    Modulators of cystic fibrosis transmembrane conductance regulator

    Vertex Pharmaceuticals Incorporated · Granted Dec 3, 2013 · Expires Nov 28, 2033

    granted

  17. US 8598210

    Prolyl hydroxylase inhibitors and methods of use

    Akebia Therapeutics, Inc. · Granted Dec 3, 2013 · Expires Nov 28, 2033

    granted

  18. US 8598174

    Pyridazinones, method of making, and method of use thereof

    GILEAD CONNECTICUT, INC. · Granted Dec 3, 2013 · Expires Nov 28, 2033

    granted

  19. US 8598191

    Controlled release compositions of gamma-hydroxybutyrate

    Supernus Pharmaceuticals, Inc. · Granted Dec 3, 2013 · Expires Nov 28, 2033

    granted

  20. US 8598181

    Modulators of ATP-binding cassette transporters

    Vertex Pharmaceuticals Incorporated · Granted Dec 3, 2013 · Expires Nov 28, 2033

    granted

  21. US 8598361

    Process for preparing 5-fluoro-1H-pyrazolo [3,4-B] pyridin-3-amine and derivatives therof

    Vertex Pharmaceuticals Incorporated · Granted Dec 3, 2013 · Expires Nov 28, 2033

    granted

  22. CA 2874019

    MELANGE GAZEUX NO/AZOTE A TENEUR ELEVEE EN NO POUR TRAITER LES DETRESSES RESPIRATOIRES HYPOXEMIANTES SEVERES

    AIR LIQUIDE SANTE INT [FR] · Granted Nov 28, 2013 · Expires Nov 23, 2033

    granted

  23. US 8592380

    Aerosol foams comprising clindamycin phosphate

    Precision Dermatology, Inc. · Granted Nov 26, 2013 · Expires Nov 21, 2033

    granted

  24. US 8592602

    Processes for producing cycloalkylcarboxamido-pyridine benzoic acids

    Vertex Pharmaceuticals Incorporated · Granted Nov 26, 2013 · Expires Nov 21, 2033

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.